MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”; OTCBB:ACTCD), a leader in the field of regenerative medicine, announced today that the US Patent and Trademark Office (USPTO) has issued U.S. patent 8,822,218 covering methods of manufacturing dendritic cells using a highly scalable processing involving a readily renewable stem cell source as the starting materials. The derivation process covered by the patent provides a means for commercial scale manufacturing of an allogeneic, off-the-shelf immunotherapy platform.
“The addition of this new patent continues to strengthen our IP position around core cell therapy components and helps protect our leading position in the regenerative medicine field,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “It is an exciting time to be here as we concentrate our efforts on developing cures for diseases and disorders of the eye and get ready to initiate phase 2 clinical trials for the treatment of Stargardt’s macular degeneration (SMD) and age-related macular degeneration (AMD).”
Hey, check out all the research scientist jobs. Post your resume today!
